.png?width=500&height=250&name=%E7%9F%A5%E7%9A%84%E8%B2%A1%E7%94%A3%E4%BA%8B%E5%8B%99%E6%89%80%E3%82%A8%E3%83%9C%E3%83%AA%E3%82%AF%E3%82%B9%20(500%20%C3%97%20250%20px).png)
For practitioners involved in filing, obtaining, and enforcing patents in Australia, this seminar...
For practitioners involved in filing, obtaining, and enforcing patents in Canada, this guide focuses on the Patent Act (R.S.C. 1985, c. P-4) and covers CIPO (Canadian Intellectual Property Office) procedures, government fees, PCT national phase entry, and unique requirements derived from English common law—such as “Manner of Manufacture / Subject Matter,” the introduction of File-Wrapper Estoppel under the 2018 Bill C-86 amendments, Patent Term Restoration (PTR) under CUSMA (USMCA) effective in 2024, and enforcement in the Federal Court—a patent attorney will systematically explain the information essential to Japanese companies’ patent strategies in the North American market.
Key Points of This Article
- Canada’s patent system is centered on the Patent Act (R.S.C. 1985, c. P-4), forming a hybrid influenced by both English common law and U.S. law
- The 2018 Bill C-86 amendment introduced File-Wrapper Estoppel—an interpretive approach previously prohibited
- CUSMA (USMCA) Compliance: Introduction of the Patent Term Restoration (PTR) system in 2024
- Certificate of Supplementary Protection (CSP): Patent term extension for pharmaceuticals (up to 2 years)
- Joined the PCT (1990). Japanese companies have a 30-month grace period for domestic PCT conversion
- Request for examination must be filed within 4 years of the filing date (for applications filed on or after October 2018)
- Enforcement of rights falls under the exclusive jurisdiction of the Federal Court
CANADA PATENT
A comprehensive guide to the patent system and practice in Canada, a key hub in the North American market, written by a patent attorney. This book systematically explains 12 key topics, ranging from CIPO applications to the major 2018 amendments, PTR and CSP, and the enforcement of rights in the Federal Court.
Table of Contents
- Executive Summary
- Basic Structure of the System and Legal Sources
- Application Procedures and Required Documents
- Standard Workflow and Timeline Management
- Estimated Government Fees
- Patent Requirements and Subject Matter
- Key Precedents and Practical Implications
- Enforcement and Infringement Response
- PCT National Phase Entry and PPH Strategies
- Maintenance, PTR, and CSP
- Differences Between Japanese and Canadian Systems
- Practical Checklist for Japanese Companies
1. Executive Summary
Canadian patent practice is a hybrid system influenced by both British common law and U.S. law, with the Patent Act (R.S.C. 1985, c. P-4) at its core. Applications, examinations, and disputes are governed by the Patent Rules, the CIPO Manual of Procedures (MOPOP), and case law from the Federal Court, the Federal Court of Appeal, and the Supreme Court.Significant modernization is currently underway following the 2018 amendments under Bill C-86 and the 2024 CUSMA implementation.
Four Key Points to Understand in Canadian Patent Practice
- Introduction of File-Wrapper Estoppel in the 2018 amendments—Application history may now be considered in litigation
- Government fees are denominated in CAD. Fees vary significantly depending on the applicant category (Standard / Small Entity)
- Examination focuses on “Subject Matter” (patentability) determinations—similar to Australia’s “Manner of Manufacture”
- Enforcement is the exclusive jurisdiction of the Federal Court. Early grant is possible through the JPO-CIPO PPH
2. Basic Structure and Legal Basis of the System
The “primary law” of the Canadian patent system is the Patent Act, R.S.C. 1985, c. P-4, which has evolved into the current system through multiple amendments.Core provisions include the definition of an invention (§2), novelty (§28.2), inventive step (§28.3), subject matter of patents (§2, §27(8)), application procedures (§§27–29), the effect of patent rights (§42), compulsory licenses (§§65–72), and criminal penalties.It underwent major revisions through Bill C-86 in 2018 and the CUSMA Implementation Act in 2024.
Role of CIPO
CIPO (Canadian Intellectual Property Office) is responsible for patent examination and registration. Its headquarters are in Gatineau (near Ottawa). It maintains an e-Filing System and a Patent Database. Procedures can be conducted in English or French.
Judicial Forums
| Courts | Jurisdiction and Characteristics |
|---|---|
| Patent Appeal Board (PAB) | Appeals against examination refusals within CIPO |
| Federal Court of Canada | Exclusive jurisdiction over patent infringement lawsuits, invalidation lawsuits, and appeals from the PAB |
| Federal Court of Appeal | Appeals from Federal Court decisions |
| Supreme Court of Canada | Court of Last Resort (Supreme Court) |
3. Application Procedures and Required Documents
Application Route
| Item | Direct Filing | Paris Convention Priority | Via PCT |
|---|---|---|---|
| Canadian Filing Deadline | Anytime | 12 months from the Japanese filing date | 30 months from the priority date |
| Language | English or French | Same as above | English specification as is |
| Agent | A patent attorney based in Canada is required | Same as above | Same as above |
Required documents
- Application Form: English or French, CIPO e-Filing
- Specification, Claims, Abstract, and Drawings: English or French
- Appointment of a Representative: A patent agent resident in Canada
- Priority Documents: Within 16 months of the filing date when claiming Paris Convention priority
- Assignment Deed: If the inventor and applicant are different (optional, but for record purposes)
4. Standard Process and Timeline Management
① Filing (CIPO e-Filing)
→
② Formal examination
→
③ Publication of application (18 months)
↓
④ Request for examination (within 4 years from the filing date) → ⑤ Substantive examination and response to Office Action → ⑥ Acceptance → Payment
of annuities ↓
⑦ Grant and registration
↓
④ Request for examination (within 4 years from the filing date) → ⑤ Substantive examination and response to Office Action → ⑥ Acceptance → Payment
of annuities ↓
⑦ Grant and registration
Timeframe: Approximately 3–5 years from filing to registration in a smooth process. Can be shortened to 1–2 years by utilizing the JPO-CIPO PPH.
5. Estimated Government Fees
| Item | Standard (CAD) | Small Entity (CAD) |
|---|---|---|
| Application Fee | CAD 555 | CAD 222 |
| Request for Examination Fee | CAD 1,110 | CAD 444 |
| Registration fee | CAD 369 | CAD 184 |
| Claim surcharge (more than 21 claims) | CAD 110 per claim | CAD 55 per claim |
| Annual fee (2nd year) | CAD 100 | CAD 50 |
| Annuity (10th year) | CAD 277 | CAD 138 |
| Pension (15th year) | CAD 462 | CAD 230 |
| Pension (20th year) | CAD 647 | CAD 322 |
Small Entity Discount: Applicable to entities with 50 or fewer employees or universities, etc., with many fees reduced by 50%. May also apply to local subsidiaries of Japanese small and medium-sized enterprises.
6. Patent Requirements and Subject Matter
Basic Requirements
- Novelty (§28.2)—Worldwide prior art standard, 12-month grace period
- Inventive Step (§28.3)—Not obvious to a person skilled in the art
- Utility (Definition of "invention" in §2) — Practical applicability
- Disclosure Requirements (§27(3))—Clarity and Enability
- Subject Matter — Determined based on the definition of "invention" in §2
Non-Patentable Subject Matter (§27(8))
- Pure scientific theories, abstract ideas, and mathematical methods
- Diagnostic, therapeutic, and surgical methods (inventions relating to pharmaceutical products are acceptable)
- Pure business methods and computer programs per se
- Plants and animals (higher life forms)—excluding biotechnology-related inventions
Introduction of File-Wrapper Estoppel in 2018
Historical Turning Point: Section 53.1 was newly established by Bill C-86 in 2018, making the prosecution history (file wrapper) admissible as evidence in claim interpretation during litigation. This introduced the U.S.-style doctrine of estoppel, which had been prohibited in Canada since the Pollard case. Since the content of arguments made in responses to Office Actions can affect future litigation, care must be taken when drafting these responses.
7. Key Case Law and Practical Implications
| Case Law | Key Issues |
|---|---|
| Schmeiser v. Monsanto (2004) | Patent infringement of genetically modified plants |
| AstraZeneca v Apotex (2017) | Abolition of the "Promise Doctrine"—Lowering of the Utility Threshold |
| Choueifaty v. Canada (2020) | Patent Eligibility of Software Inventions—Criticism of the “Problem-Solution” Approach |
| Whirlpool v. Camco (2000) | Basic Principles of Claim Interpretation (Purpose-Based Interpretation) |
8. Enforcement and Response to Infringement
Enforcement of Rights in the Federal Court
Remedies in the Federal Court of Canada
- Injunctions (Interim and Permanent)
- Alternative Claims for Damages or the Infringer’s Profits
- Punitive Damages — Intentional or Willful Infringement
- Order for the Surrender or Destruction of Infringing Goods
PMNOC (Patented Medicines (Notice of Compliance) Regulations)
In the pharmaceutical sector, the Patented Medicines (Notice of Compliance) Regulations establish a unique procedure. It functions as a patent linkage system when generics enter the market.
9. PCT National Phase Entry and PPH Strategy
Canada joined the PCT in 1990. PCT national phase entry is possible within 30 months of the priority date (with a maximum 12-month extension available, subject to a surcharge). By utilizing the JPO-CIPO PPH, early examination can be obtained based on claims granted in Japan.
JPO-CIPO PPH: Operational since 2008; available free of charge. Reduces processing time from the usual 3–5 years to 1–2 years. Canada also participates in the Global PPH (IP5+α).
10. Maintenance, PTR, and CSP
The term of a patent is 20 years from the filing date. Annual fees are payable every year starting from the second year (accruing even before the patent is granted). A 12-month grace period is available for late payments.
Patent Term Restoration (PTR; 2024)
New system in response to CUSMA
- Effective January 1, 2024
- Compensation for CIPO examination delays (exceeding 5 years or exceeding 3 years from the request for examination)
- Maximum extension period calculated based on the duration of the delay
- Filing fee: CAD 2,500
Certificate of Supplementary Protection (CSP)
Supplementary Protection for Medicines
- Introduced in 2017 (in response to CETA)
- Compensation for time lost due to regulatory compliance for pharmaceuticals (up to 2 years)
- Application Deadline: Within 120 days of pharmaceutical approval
- Application fee: CAD 1,250
11. Differences Between the Japanese and Canadian Systems
| Item | Japan | Canada |
|---|---|---|
| Language of Application | Japanese | English or French |
| Representative | Patent Attorney | Patent Attorney based in Canada |
| Deadline for Request for Examination | 3 years (from the filing date) | 4 years (from the filing date, for applications filed on or after October 2018) |
| PCT National Phase Entry | 30 months | 30 months (extendable by 12 months) |
| Start of annuity payments | After registration | From the second year of the application (prior to grant) |
| File-Wrapper Estoppel | Available | Introduced in 2018 |
| Patent Term Extension | Pharmaceutical PTE | PTR (2024) + CSP (2017) |
12. Practical Checklist for Japanese Companies
Pre-filing
- Appointment of a Canadian-based patent attorney (required)
- Preliminary evaluation of subject matter eligibility (especially for software inventions)
- Confirmation of Standard/Small Entity classification
- Optimize the number of claims (additional fees apply for more than 21 claims)
During Filing
- Request for examination must be filed within 4 years of the filing date (for applications filed on or after October 2018)
- Early examination via JPO-CIPO PPH
- Pay close attention to the arguments made in responses to Office Actions (due to File-Wrapper Estoppel)
- Strictly adhere to the response deadline (4 months)
After Filing
- Annuities are due annually starting from the second year (accruing from before grant)
- File a lawsuit in Federal Court upon discovery of infringement
- For pharmaceuticals, file a CSP application (within 120 days of approval)
- Consider filing a PTR application in case of examination delays
Summary
The Canadian patent system is undergoing modernization, including the introduction of File-Wrapper Estoppel in 2018 and the Patent Term Restoration system in 2024. For Japanese companies to succeed in their patent strategies in the Canadian market, it is crucial to combine the use of the JPO-CIPO PPH with effective enforcement of rights in the Federal Court, and—in the case of pharmaceuticals—to ensure that CSP and PTR applications are not overlooked. Please also see our PCT international patent applications and patent application services.
Consultation on Canadian Patent Applications
EVORIX Intellectual Property Law Firm provides comprehensive support for patent applications and enforcement in major North American countries, including Canada. Our experienced patent attorneys, working in collaboration with local agents, handle everything from subject matter compliance and PPH strategies to CSP/PTR utilization and infringement responses in the Federal Court.
Sources & References
▼ Primary Legislation
- Patent Act, R.S.C. 1985, c. P-4 (Patent Act) + multiple amendments
- Patent Rules
- Bill C-86 (2018; File-Wrapper Estoppel and Small Entity Amendments)
- CUSMA Implementation Act (2024 – Introduction of PTR)
- Patented Medicines (Notice of Compliance) Regulations (Pharmaceutical Linkage)
- Certificate of Supplementary Protection Regulations (CSP; 2017)
▼ Major Case Law
- Schmeiser v Monsanto (2004, Supreme Court)
- AstraZeneca v Apotex (2017, Supreme Court) — Abolition of the Promise Doctrine
- Choueifaty v Canada (2020, Federal Court) — Software Patents
- Whirlpool v. Camco (2000, Supreme Court) — Claim Interpretation
▼ Official Sources
- CIPO Official Website: ic.gc.ca/cipo
- Canadian Patents Database: ic.gc.ca/cpd
- WIPO IP Portal (Canada): wipo.int
- Federal Court of Canada: fct-cf.gc.ca
- PCT Member (1990): WIPO PCT System
- MOPOP (CIPO Examination Manual): CIPO Official
▼ Explanatory materials from Japanese agencies
- JETRO Report: "Intellectual Property System in Canada"
- Japan Patent Office “Information on Foreign Industrial Property Rights Systems (Canada)”
- INPIT Intellectual Property Information on Emerging Countries
▼ International Agreements
- Paris Convention (Canada joined in 1925)
- PCT (Canada joined in 1990)
- TRIPS Agreement (WTO Member since 1995)
- USMCA/CUSMA (Entered into force in 2020)
- CPTPP (Entered into force in 2018)
- CETA (Canada-EU) (Entered into force in 2017)
*This article is based on the above primary sources and official information as of April 2026 and is intended to provide general information. As laws and regulations are subject to change, we recommend consulting primary sources and experts for the most up-to-date information. For specific decisions regarding individual cases, we recommend consulting experts, including local representatives.
AUTHOR / Author
Takefumi Sugiura
Representative Patent Attorney, EVORIX Intellectual Property Firm
Assists clients across a wide range of industries—including IT, manufacturing, startups, fashion, and healthcare—from patent, trademark, design, and copyright applications through to trials and infringement litigation. Also well-versed in intellectual property strategies for cutting-edge fields such as AI, IoT, Web3, and FinTech. Member of multiple organizations, including the Japan Patent Attorneys Association, the Asian Patent Attorneys Association (APAA), and the Japan Trademark Association (JTA).